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Abstract: Parkinson’s disease (PD) afﬂ  icts millions of people worldwide and leads to cognitive 
impairment or dementia in the majority of patients over time. Parkinson’s disease dementia 
(PDD) is characterized by deﬁ  cits in attention, executive and visuospatial function, and memory. 
The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with 
evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer’s disease 
(AD). Cortical cholinergic deﬁ  cits are greater in PDD than in AD, and are well-correlated with 
the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine 
metabolism is therefore a practical therapeutic strategy in PDD.
This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholin-
esterase inhibitor) treatment in PDD. In addition to its efﬁ  cacy, we examine the safety proﬁ  le, 
side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest 
beneﬁ  t in PDD and further long-term studies are needed to determine the effectiveness and 
safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with 
rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such 
as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous 
patient/caregiver quality of life assessments.
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Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
behind Alzheimer’s disease (AD). James Parkinson (1817) ﬁ  rst described PD in his 
seminal work “An Essay on the Shaking Palsy.” The cardinal motor signs of PD (bra-
dykinesia, resting tremor, cogwheel rigidity, postural instability) are emphasized in 
making the diagnosis and in tracking progression of the disease (Gibb and Lees 1988). 
Most recently, signiﬁ  cant attention has been given to the non-motor symptoms of PD, 
including constipation, depression, olfactory dysfunction and dementia (Chaudhuri 
et al 2006). Parkinson (1817) was keenly aware of many non-motor aspects of PD 
including constipation and disturbed sleep. He did not recognize, however, impaired 
olfaction and dementia as a part of the disease describing “the senses and intellects” 
as “being uninjured” (Parkinson 1817). His lack of recognition of PD as a dementing 
illness is understandable given life expectancy in Great Britain in the early 19th century 
was under 40-years, and we now know that the risk of Parkinson’s disease dementia 
(PDD) increases with age (Levy et al 2002).
PDD has perhaps been more studied and emphasized of late for several reasons: 
(1) greater emphasis on the non-motor symptoms of PD (Chaudhuri et al 2006), (2) 
the emergence of cholinesterase inhibitors as effective treatments in AD and PDD, 
and (3) ruling-out dementia is important in PD patients being considered for deep 
brain stimulation surgery (given it is exclusionary). We do know that PDD is under 
recognized and under treated in routine clinical practice. Recent studies have dem-
onstrated that cognitive decline and/or PDD afﬂ  icts the majority of patients with PD Neuropsychiatric Disease and Treatment 2007:3(6) 776
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over time (Aarsland et al 2003; Hely et al 2005) and that this 
signiﬁ  cantly contributes to increased morbidity and mortality 
(Levy et al 2002; Hughes et al 2004; de Lau et al 2005).
Deﬁ  ning Parkinson’s disease 
dementia (PDD)
According to DSM-IV criteria (APA 2000), dementia is 
characterized by “the development of multiple cognitive 
deﬁ  cits that include memory impairment and at least one 
of the following cognitive disturbances: aphasia, apraxia, 
agnosia, or disturbance in executive dysfunction. The cogni-
tive deﬁ  cits must be sufﬁ  ciently severe to cause impairment 
in occupational or social functioning and must represent 
a decline from a previously higher level of functioning.” 
Major cognitive domains that can be affected in dementia 
include: (1) executive function, (2) recent memory, (3) 
language, and (4) visuospatial function. PDD is more of a 
subcortical dementia with prominent deﬁ  cits in executive 
and visuospatial function typically more so than language 
and recent memory (Cummings 1988; Rippon and Marder 
2005). PDD is also characterized by generalized cognitive 
slowing (bradyphrenia) and impaired attention (Cummings 
1988; Rippon and Marder 2005).
Mild cognitive impairment (MCI) is differentiated from 
dementia in that it represents a borderland between normal 
cognition and dementia. MCI remains controversial with 
some clinicians viewing this entity as a disease along a 
pathway leading to fulminant AD, while others view MCI 
as a heterogeneous syndrome representing an early stage of 
different forms of dementia (Fernandez et al 2005). Cogni-
tive decline is perhaps the rule as PD progresses (Hely et al 
2005); however, the deﬁ  nition of MCI in PD is even less 
well-deﬁ  ned than the deﬁ  nition of PDD (Fernandez et al 
2005).
Given clinical and neuropathological overlap, the most 
important distinction in the diagnosis of PDD is attempting 
to distinguish it from dementia with Lewy bodies (DLB) 
(Aarsland et al 2005; McKeith et al 2005). Clinically, patients 
with DLB are typically characterized as having early demen-
tia and parkinsonism with less robust response to levodopa, 
ﬂ  uctuations in level of alertness, visual hallucinations in the 
absence of dopaminergic treatment, rapid progression of 
dementia, and severe sensitivity to typical and some atypi-
cal antipsychotics (Fuchs et al 2004; McKeith et al 2005). 
Unfortunately, neuropsychological testing may not be able 
to distinguish between patients with these two entities (Noe 
et al 2004), and the timecourse of the development of the 
dementia is perhaps most important.
For an operational method of distinguishing PDD from 
DLB, PDD has recently been deﬁ  ned as the onset of dementia 
at least one year after the appearance of Parkinsonian motor 
symptoms (McKeith et al 2005). This deﬁ  nition is artiﬁ  cial 
and not typically representative of clinical experience (where 
patients become demented after many years of PD (Aarsland 
et al 2005)) and maybe difﬁ  cult to apply in practice. The 
largest clinical trial in PDD (Emre et al 2004) included 
patients meeting established clinical diagnostic criteria for 
PD (Gibb and Lees 1988) and fulﬁ  lling DSM-IV criteria for 
PDD with onset at least two years after the diagnosis of PD 
(Emre et al 2004).
Neuropathologically PDD overlaps with DLB and AD 
in numerous studies (Mahler and Cummings 1990; Perl et al 
1998; Aarsland et al 2004; Galvin et al 2006). Dementia with 
Lewy Bodies (DLB) and PDD are typically categorized as 
two separate disease states with distinct pathologies, but 
debate continues as to whether DLB and PDD are, in fact, 
along the same disease spectrum (Levy et al 2006; Galvin et al 
2006; Padovani et al 2006). AD pathology has been noted 
in many demented and non-demented patients with PD and 
estimates of AD pathology among PD patients at autopsy 
are as high as 42%–91% (Galvin et al 2006; Padovani et al 
2006). Although these changes are present in a large propor-
tion of patients with PD, it is difﬁ  cult to deﬁ  ne the role these 
changes play in the cognitive decline in PD.
It is also suggested that the cognitive dysfunction devel-
oping later in Parkinson’s is due to the loss of cholinergic 
neurons in the nucleus basalis of Meynert (Whitehouse et al 
1987). Supporting this hypothesis, there is evidence that 
cortical cholinergic deﬁ  cits are more pronounced in PD 
than in AD and well-correlated with cognitive decline and 
neuropsychiatric disturbances in PD (Bohnen et al 2003; 
Hilker et al 2005).
Most recently, Aarsland et al (2005) reported the neu-
ropathology of 22 PD patients identiﬁ  ed in the community 
and followed prospectively until death. Eighteen of the 
22 patients (82%!!) were diagnosed with dementia with none 
of the 18 meeting established neuropathological criteria for 
AD (Aarsland et al 2005). All 18 demented patients had 
limbic and neocortical Lewy bodies (Aarsland et al 2005) 
however. In accord with clinical practice, the average disease 
duration for these patients was approximately 16 years with 
a diagnosis of dementia occurring a mean of three years 
before death (Aarsland et al 2005). It thus appears that lim-
bic and neocortical Lewy bodies associated with signiﬁ  cant 
cholinergic deﬁ  cits are perhaps the main substrate for the 
development of PDD.Neuropsychiatric Disease and Treatment 2007:3(6) 777
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Risk factors and epidemiology
of PDD
The Apo ε2 allele, older age at onset, the presence of depres-
sion, development of visual hallucinations, severity of dis-
ease, and an akinetic-rigid phenotype are established risk 
factors for the development of PDD (Marder et al 1995; Levy 
et al 2002; de Lau et al 2005; Burn et al 2006). The incidence 
and prevalence of PDD depends upon the neuropsychological 
tests and the criteria used to deﬁ  ne PDD and neuropsycho-
logical testing batteries can vary considerably from center 
to center (Defer et al 1999; Saint-Cyr and Trepanier 2000; 
Pillon 2002; Burn et al 2006; Voon et al 2006).
The incidence of PDD varies widely across studies with 
the greatest incidence in elderly PD patients. The risk of 
developing dementia in PD is estimated to be 6 times that of 
age-matched controls (Padovani et al 2006). Early estimates 
of the prevalence of dementia in PD were in the range of 20% 
(Brown and Marsden 1984). Cummings (1988) estimated that 
as many as 40 percent of PD patients cross-sectionally have 
PDD. More recently, Aarsland et al (2003) found that 78% 
of PD patients followed for 8 years develop PDD (Aarsland 
et al 2003).
The prevalence of MCI in PD is largely unknown 
(Fernandez et al 2005). Cognitive decline, perhaps consistent 
with MCI, was present in 84% of survivors from a cohort 
of PD patients followed 15-years after diagnosis (Hely et al 
2005). Forty-eight percent of these survivors fulﬁ  lled criteria 
for dementia (Hely et al 2005). Consistent with these ﬁ  ndings, 
most PD patients undergoing neuropsychological testing to 
exclude dementia before deep brain stimulation surgery display 
some level of cognitive dysfunction (typically executive dys-
function) (Saint-Cyr et al 2000; Pillon 2002). Cognitive decline 
is therefore perhaps a ubiquitous feature as PD progresses.
Rivastigmine
Acetylcholinesterase (AChE) inhibitors have been the main-
stay of treatment in AD for many years. In AD, these drugs 
have been shown to slow symptomatic decline in cogni-
tion over time, delay nursing home placement, and result 
in lower long-term healthcare costs for patients/families 
(Geldmacher 2005). AChE inhibitors theoretically improve 
cognitive function by increasing acetylcholine in the brain 
through preventing its breakdown. There are numerous 
AChE inhibitors commercially available including donepezil, 
galantamine, rivastigmine, and tacrine. All of these drugs 
are effective in AD, however there is relatively little data 
on their use in PDD.
Rivastigmine is a second generation, carbamate-type, 
reversible, brain selective cholinesterase inhibitor (Enz et al 
1991). It appears to be more selective for the monomeric form 
of AChE that is predominantly in the cortex and hippocampus 
relative to peripheral forms of AChE (Enz et al 1993). It is 
dosed twice daily titrating from 1.5 mg twice per day up to 
6 mg twice per day as tolerated. The majority of patients 
tolerate total doses of 6 mg/day or higher. Rivastigmine is 
slightly different than donepezil and galantamine given it 
has both AChE inhibitory activity and butyrylcholinesterase 
inhibitory activity. Inhibition of both forms of cholinesterase 
has theoretical advantages in allowing greater endogenous 
levels of acetylcholine, but it is unknown if this drug provides 
beneﬁ  ts above and beyond other AChE inhibitors given head-
to-head studies have not been done.
Clinical trials of rivastigmine in DLB 
and PDD
Donepezil and galantamine have only been studied 
in open-label studies or small scale clinical trials in 
Table 1 Placebo-controlled cholinesterase inhibitor trials in PDD and DLB
Authors  Medication  Study design  Number of patients  Study duration  Diagnostic criteria for
         PDD/DLB
McKeith et al (2000)  Rivastigmine  DB, PC  120  23 weeks  Probable DLB, mild to 
         moderate  dementia 
         with  MMSE  9
Aarsland et al (2002)  Donepezil  DB, PC, CO  14  10 weeks  DSM-IV/probable PDD
Leroi et al (2004)  Donepezil  DB, PC  16  18 weeks  DSM-IV or symptoms
          consistent with PDD
Emre et al (2004)  Rivastigmine  DB, PC  541  24 weeks  DSM-IV, mild to mod-
          erate dementia with 
          MMSE of 10–24
Ravina et al (2005)  Donepezil  DB, PC, CO  22  10 weeks  DSM-IV, mild to mod-
          erate dementia with
         MMSE  17–26
Abbreviations: DB, double-blind; PC, placebo-controlled; CO, cross-over.Neuropsychiatric Disease and Treatment 2007:3(6) 778
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PDD (Table 1). Rivastigmine has been studied in large 
randomized, placebo-controlled clinical trials in DLB 
(McKeith et al 2000) and PDD (Emre et al 2004) (Table 1). 
The data available for rivastigmine has led to the approval 
of this medication in the treatment of PDD in Europe, the 
United States and elsewhere.
McKeith et al (2000) studied the efﬁ  cacy of rivastig-
mine in DLB. In this randomized, double-blind, placebo-
controlled study, participants were given placebo or titrated 
up to 12 mg/day of rivastigmine for 20-weeks followed by 
a 3-week washout period. Assessments were made at base-
line, and at 12-, 20-, and 23-weeks. Neuropsychiatric testing 
and computerized cognitive assessments were performed at 
each session. Signiﬁ  cant clinical and cognitive performance 
improvements were noted in those receiving rivastigmine as 
compared with placebo. Thirty-seven subjects (63%) in the 
rivastigmine group showed at least a 30 percent improve-
ment from baseline as compared to only 18 subjects (30%) 
of the placebo group. Patients improved most in the areas of 
apathy and indifference and had fewer hallucinations than 
those receiving placebo.
As previously discussed, it is becoming more evident that 
DLB and PDD are on a continuum of disease, with signiﬁ  cant 
overlap in terms of clinical and cognitive signs and symptoms 
(Aarsland et al 2005; Galvin et al 2006; Padovani et al 2006). 
Given the obvious clinical beneﬁ  ts of rivastigmine in DLB 
(McKeith et al 2000), this led to further study in patients 
deﬁ  ned as having PDD.
In an open label trial by Reading et al (2001), twelve 
patients with PD-related cognitive impairment and psychosis 
were given rivastigmine at an initial dose of 1.5 mg twice 
daily and then titrated to 6 mg twice daily or the highest 
tolerated dose. Patients were assessed at 8-weeks after 
the maximum titration level was reached and once again 
6-weeks after that period. The drug was discontinued at that 
point and participants were assessed once again 3-weeks 
after withdrawal of rivastigmine. At each session, the Fol-
stein Mini-Mental Status Exam (MMSE) was utilized as a 
measure of cognition and the Uniﬁ  ed Parkinson’s Disease 
Rating Scale (UPDRS) was administered to evaluate the 
motor symptoms of PD. Neuropsychiatric symptoms were 
evaluated using the Neuropsychiatric Inventory (NPI), which 
evaluates behaviors over the preceding four weeks. Cognitive 
assessment utilizing the MMSE revealed signiﬁ  cant improve-
ment of 5 points in patients on rivastigmine relative to their 
baseline (Z = 2.81, p   0.005). Motor symptoms and signs 
were unchanged as measured by UDPRS (Z = 1.18, p   0.2). 
NPI scores were also significantly lowered (improved) 
from baseline on treatment (Z = 2.85, p   0.004). Patients 
worsened signiﬁ  cantly three weeks after withdrawal of the 
rivastigmine (Reading et al 2001).
Giladi et al (2003) also studied the efﬁ  cacy of rivastig-
mine in the treatment of PDD. In this open label study, 20 of 
28 patients completed 26-weeks of treatment with rivastig-
mine therapy (as tolerated up to 12 mg/day). The MMSE and 
Alzheimer’s Disease Assessment Scale (ADAS-cog) were 
used as cognitive measures and the UPDRS for documenting 
Parkinsonian features. Patients were assessed prior to start-
ing therapy, at 12 and 26-weeks while on rivastigmine, and 
8-weeks after withdrawal of therapy. Eight of the 28 patients 
dropped out secondary to side effects. An increase in UDPRS 
score was observed from baseline to week 26 (p   0.06) and 
a non-signiﬁ  cant improvement was noted from week 26 to 
8-weeks after treatment washout. Signiﬁ  cant improvement 
was noted in the area of the attentional components of the 
MMSE at week 26 (p   0.002). In terms of the ADAS-cog, 
a signiﬁ  cant increase in total score (worsening) was noted 
throughout the study period (p = 0.002).
The authors indicated that the objective cognitive mea-
sures (MMSE and ADAS-cog) did not at all reﬂ  ect the clini-
cal impressions of the caregivers for the patients in the study. 
In particular, caregivers seemed surprise by the deterioration 
experienced after washout. This, again, suggests the need for 
a cognition assessment tool that is validated and best utilized 
in PD. Giladi et al (2003) also noted increased tremor in 
eleven of the original 28 participants in the study and dose 
reduction was required.
In this study, it would be expected for patients to worsen 
on the UPDRS over 6-months whether they were on an AChE 
inhibitor or not. A non-signiﬁ  cant trend for improvement in 
the UPDRS scores following washout, however would make 
one consider that rivastigmine negatively inﬂ  uenced motor 
performance. An increase in tremor and parkinsonism was 
a legitimate concern in this study given we still use anticho-
linergics for some patients with PD (certainly not demented 
ones, though!) (Morgan and Sethi 2005). There were prior 
case reports of worsening of tremor and parkinsonism in PD 
patients treated with AChE (Richard et al 2002). The results 
of the Reading et al (2001) and Giladi et al (2003) studies 
indicated further need to study the effects of this drug on 
cognition and parkinsonism in PDD in a prospective, double-
blind, placebo-controlled fashion.
In 2003, Fogelson et al (2003) performed another open 
label study examining the effects of rivastigmine on quan-
titative EEG (qEEG) in PDD patients (n = 19), given they 
frequently have a slowing of alpha activity on EEG. Patients Neuropsychiatric Disease and Treatment 2007:3(6) 779
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were treated with rivastigmine at an initial dose of 3 mg/day 
and titrated to a dose of 12 mg/day or highest tolerated dos-
age. Quantitative EEG recordings were performed prior to 
introduction of rivastigmine and repeated when the patients 
had been on treatment for 12-weeks. A signiﬁ  cant increase 
in the relative alpha activity was noted after treatment with 
rivastigmine (p = 0.019), however, no correlation between 
qEEG changes and cognitive improvement was identiﬁ  ed 
(Fogelson et al 2003). It is difﬁ  cult, therefore, to determine 
whether these qEEG changes were due to improvement in 
cognitive state rather than just an increase in arousal.
A sound neuropathological and pharmacological basis 
and promising open label studies were followed by the pub-
lication of a multi-center, placebo-controlled, double-blind 
study in 541 patients with PDD (Emre et al 2004). PD was 
diagnosed using the UK PD Brain Bank Criteria and dementia 
was diagnosed using DSM-IV criteria. Participants were 
randomly assigned to receive placebo or 3–12 mg (titrated to 
the maximum tolerated dose over a 16-week dose escalation 
period) of rivastigmine divided twice daily for 24-weeks. 
Patients were randomized 2:1 to rivastigmine and placebo, 
respectively. The primary outcome measures were the 
ADAS-cog scores as in previous open label studies (Fogelson 
et al 2003; Giladi et al 2003) and the Alzheimer’s Disease 
Cooperative Study-Clinician’s Global Impression of Change 
(ADCS-CGIC). There were six secondary outcome measures: 
Alzheimer’s Disease Cooperative Study – Activities of 
Daily Living (ADCS-ADL), NPI, MMSE, Cognitive Drug 
Research Power of Attention tests (CDR), Delis-Kaplan 
Executive Function System (D-KEFS) verbal ﬂ  uency test, 
and the Ten Point Clock-Drawing Test. Safety monitoring 
included recording of adverse events, monitoring ECGs and 
laboratory data, vital signs and body weight. Patients were 
also assessed for changes in parkinsonism from baseline 
scores at weeks 16 and 24 using the UPDRS part III (motor 
section) score.
Patients were included in the efﬁ  cacy analysis if they 
underwent a baseline evaluation and if they took one dose 
of study medication followed by an assessment of the one 
of the efﬁ  cacy variables after baseline (regardless if they 
were taking study medication at the time). If no follow-
up information was available Emre et al (2004) used the 
last-observation-carried-forward method to impute missing 
values for missing follow-up information.
Approximately 30%–35% of patients enrolled in the 
study suffered with co-morbid psychiatric disorders (includ-
ing depression, anxiety, and psychosis) (Emre et al 2004). 
The average age of patients was approximately 72 with PD 
diagnosis 9-years earlier on average. Essentially all of the 
patients were Caucasian and approximately 2/3 were men. 
The mean time since the diagnosis of PDD for patients 
entering the study was approximately 13–15 months. There 
were no signiﬁ  cant demographic differences between the 
two treatment groups.
As compared to patients in the placebo group, patients 
who received rivastigmine demonstrated signiﬁ  cant improve-
ments in ADAS-cog and ADCS-CGIC scores (primary 
efﬁ  cacy variables) (Emre et al 2004). Patients that were 
treated with rivastigmine had a mean improvement of 
2.1 points in the ADAS-cog, while patients in the placebo 
group had a 0.7 point worsening (p, 0.001). Clinically mean-
ingful improvement was observed in the investigator rated 
ADS-CGIC in 19.8% or rivastigmine patients and 14.5% in 
placebo-treated patients, while clinically meaningful wors-
ening was evident in 13.0% and 23.1 percent, respectively 
(p = 0.007). At week 24, rivastigmine provided improvement 
in all six secondary efﬁ  cacy variables relative to the baseline 
evaluation, while placebo-treated patients remained the same 
(NPI) or worsened (ADCS-ADL, MMSE, CDR, D-KEFS, 
Ten Point Clock-Drawing Test) (Emre et al 2004). These 
beneﬁ  ts should be considered moderate and in-line with other 
clinical trials of AChE inhibitors in AD.
A total of 410 out of 541 patients enrolled completed 
the study. Ninety-nine patients dropped out of the study in 
the rivastigmine arm with 32 dropping-out in the placebo 
arm. Approximately two-thirds of the drop-outs in the riv-
astigmine arm were due to adverse events and less than half 
of the drop-outs in the placebo arm were due to the same. 
Cholinergic symptoms typical of AChE inhibitors were 
the most common adverse events, with nausea reported by 
29% of rivastigmine – vs 11.2% of placebo-treated patients 
(p   0.001) and vomiting by 16.6% vs 1.7% respectively. 
In general, Parkinsonian symptoms as a whole were more 
often reported by patients in the rivastigmine group relative 
to placebo (27.3% vs 15.6%, p = 0.002). Tremor (10.2% 
vs 3.9%) and dizziness (5.8% vs 1.1%) were also reported 
more often as an adverse event in rivastigmine-treated 
patients. Tremor only caused withdrawal of 1.7% of patients 
in the rivastigmine group and no one in the placebo group 
(p = 0.19). There was no signiﬁ  cant difference in UPDRS 
motor scores and tremor related items between the groups, 
however. Interestingly, hallucinations (4.7% vs 9.5%) and 
orthostatic hypotension (1.7% vs 5.0%) were reported more 
often in patients treated with placebo.
In a letter to the editor, Harada et al (2005) argued that 
the number needed to treat in order to reach what Emre et al Neuropsychiatric Disease and Treatment 2007:3(6) 780
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(2004) deﬁ  ned as “clinically meaningful improvement” does 
not outweigh the side effects experienced by the participants 
in the study. Harada et al (2005) only considered those who 
had “clinically meaningful beneﬁ  t” in their analysis, how-
ever, and an important factor in any progressive neurodegen-
erative dementia is how many patients were prevented from 
“clinically meaningful worsening” as well.
The results of the Emre et al (2004) study are encourag-
ing for the use of rivastigmine in PDD, however the efﬁ  cacy 
is modest. Adverse events are common with rivastigmine 
and typically cholinergic in nature, however they usually 
do not result in discontinuation of the drug. This study was 
hampered by lack of a validated assessment tool for PDD. 
The ADAS-cog and the ADCS-CGIC as primary efﬁ  cacy 
variables are appropriate, however there needs to be further 
validation of this scale in PDD. Fortunately, six additional 
tests of cognitive domains that would be impaired in PDD 
were also used (CDR, etc.). The ﬁ  nding of fewer reported 
hallucinations in the rivastigmine-treated arm is interesting 
given this drug may not only provide stabilization and slower 
decline of cognitive function in PDD, it may also help reduce 
hallucinations, which can be quite troubling for patients and 
caregivers alike.
Another concern is the cost of this drug relative to the 
beneﬁ  t. Is the modest beneﬁ  t obtained enough to delay nurs-
ing home placement and is it cost-effective over time? Should 
NMDA-receptor antagonists such as memantine be added to 
PDD as it advances? Are the other AChE inhibitors equally 
efﬁ  cacious in PDD?
There was an open-label extension to the Emre et al 
(2004) study published recently by Poewe et al (2006). Of 433 
patients that completed the double-blind trial, 334 entered and 
273 completed the active treatment extension study (3–12 
mg rivastigmine/day). At 48-weeks the ADAS-cog score had 
improved by 2 points above baseline for the entire group of 
patients. Patients in the placebo treatment arm in the original 
Emre et al (2004) trial also had a 2-point improvement in 
their ADAS-cog score. The safety proﬁ  le of rivastigmine 
in the open label extension was similar to the double-blind 
phase (Poewe et al 2006).
Wesnes et al (2005) looked speciﬁ  cally at the effects of 
rivastigmine on attention in PDD in patient enrolled in the 
Emre et al (2004) trial. In this sub-study, 487 patients with 
PDD were given rivastigmine or placebo and assessed at 
baseline, 16 and 24-weeks. Assessment of attention on the 
Cognitive Drug Research (CDR) computerized assessment 
was performed at each visit in order to assess attention during 
various tasks. As compared with placebo, signiﬁ  cant beneﬁ  ts 
on attention were noted among the rivastigmine group. Dif-
ﬁ  culty maintaining attention is a common ﬁ  nding in PDD and 
further asserts that rivastigmine is helpful for this impairment 
in these patients (Wesnes et al 2005).
Economic evaluation of rivastigmine was examined soon 
after positive studies on PDD were published. Willan et al 
(2006) prospectively examined the cost effectiveness of riv-
astigmine in the Emre et al (2004) treated patients. Quality 
adjusted survival time (QAST) score was transformed from 
the MMSE score and utilized as a measure of cost effective-
ness. Although an increase in QAST in the rivastigmine 
arm of 2.81 quality-adjusted life-days was noted (two-sided 
p-value 0.13 [90% CI –0.243, 5.86]), no between-treatment 
differences in cost were seen. The high variability in cost of 
medications (the study looked at Canadian and UK prices) 
as well as the short duration of the study (six months) could 
have interfered with the examination of cost effectiveness 
and further studies need to be performed.
Patients with PDD and DLB can often have autonomic 
nervous system dysfunction, and AChE can potentially 
increase acetylcholine and contribute to cardiac dysfunction. 
Ballard et al (2006) reviewed cardiac safety of rivastigmine 
in DLB and PDD. Reviewing the Emre et al (2004) PDD trial 
(n = 541) and the McKeith et al (2000) DLB trial (n = 120), 
no clinically meaningful treatment differences in bradycardia 
or abnormalities on ECG were noted. Patients treated with 
rivastigmine did have a mean reduction of 1.5–2 beats per 
minute in heart rate, however. In fact, compared with placebo, 
it appears that rivastigmine was associated with fewer adverse 
events (p = 0.002) and fewer syncopal episodes (p = 0.018) 
among PDD patients (Ballard et al 2006).
Discussion
A recent practice parameter from the American Academy 
of Neurology indicated that there was Level B evidence 
(moderately strong) for the treatment of PDD with either 
donepezil or rivastigmine (Miyasaki et al 2006). Given the 
lack of published large, randomized, placebo-controlled trials 
of donepezil in PDD, we feel that rivastigmine currently has 
the best data for use in PDD. The beneﬁ  ts are modest and 
further studies are needed, but the Emre et al (2004) data 
are the best that we have in the use of AChE inhibitors in 
PDD and the clinically and pathologically similar condition 
DLB (McKeith et al 2002). The dropout rate in the placebo-
controlled phase was higher in the rivastigmine-treated 
PDD patients vs placebo-treated patients (27.3% vs 17.9%) 
(Emre et al 2004) and using LOCF analytical techniques 
in a progressive condition like PDD would artifactually Neuropsychiatric Disease and Treatment 2007:3(6) 781
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show less worsening in the rivastigmine treated group. The 
number needed to treat to provide a clinically meaningful 
signiﬁ  cant outcome in the Emre et al (2004) trial is perhaps 
six if you consider both meaningful improvement in the 
rivastigmine arm combined with the group with clinically 
meaningful worsening in the placebo-treated arm (Aarsland 
et al 2006).
Given the relatively high drop-out rate in rivastigmine-
treated patients, the safety proﬁ  le of rivastigmine should be 
further examined. Future studies need to speciﬁ  cally explore 
the gastrointestinal side effects and patient perceived wors-
ening of motor symptoms (ie, especially tremor). To this 
end, a recent study of 26 patients with PDD on rivastigmine 
revealed only mild worsening of tremor by accelerometry 
and a global tremor rating scale based upon the UPDRS 
(Gurevich et al 2006). Further study of the possible positive 
inﬂ  uence of rivastigmine on the neuropsychiatric symptoms 
of PDD (hallucinations and delusions) is warranted given 
these problems were reported signiﬁ  cantly less as adverse 
events in the rivastigmine arm of the Emre et al (2004) 
placebo-controlled study. It will be interesting to see if the 
other AChE inhibitors like donepezil (a drug with fewer 
reported adverse events in AD trials (Birks 2006)) provide 
similar efﬁ  cacy in PDD with fewer side effects (Aarsland 
et al 2002; Leroi et al 2004; Ravina et al 2005).
It is also necessary to look at the cost of rivastigmine 
versus the beneﬁ  ts gained by patients and caretakers. While 
there is good pharmacoeconomic data in AD for various 
AChE inhibitors (Geldmacher 2005), it is lacking for these 
drugs in PDD. A pharmacoeconomic assessment performed 
by Willan et al (2006) was possibly not signiﬁ  cant because 
of the variability of drug costs and the short, six-month study 
period. Alternatively, the costs may outweigh the beneﬁ  ts 
of rivastigmine in PDD. Looking ahead, we must examine 
costs over a longer treatment horizon. A confounding factor 
in PDD is that progression and severity of motor symptoms 
can lead to long-term care in patients with PD, which is 
somewhat different than in AD where patients are typically 
put in a nursing home due to severe dementia.
The publication of the efﬁ  cacy of rivastigmine in PDD 
could be regarded as “the carriage coming before the horse” 
so to speak. In our opinion, a well-deﬁ  ned, clinically and 
neuropathologically relevant deﬁ  nition of PDD must be 
developed. The Movement Disorders Society has assembled 
a task force to develop this deﬁ  nition and the outline of 
this new deﬁ  nition was presented at the 10th International 
Conference of Parkinson’s Disease and Movement Disor-
ders in Kyoto, Japan in 2006. This deﬁ  nition of PDD will 
hopefully be published in its entirety soon. While a decline 
in premorbid function will be necessary for the diagnosis of 
PDD with impairment in at least two cognitive domains, it 
appears that memory impairment on the MMSE (score   25) 
will not be a required feature to make the diagnosis of PDD 
by these criteria. The current deﬁ  nition of PDD is largely 
based on the deﬁ  nition of dementia as cited in the DSM-IV 
with a decline in functional level, memory decline and at 
least one additional form of cognitive impairment (executive 
dysfunction, apraxia, agnosia, aphasia) (Fuchs et al 2004) 
and by exclusion of PDD from those with DLB (McKeith 
et al 2005).
Screening and assessment tools for MCI in PD patients 
and in PDD must be identiﬁ  ed, developed and validated. If 
you examine various neuropsychological testing batteries 
recommended for evaluation of cognitive function in PD, 
you will ﬁ  nd a hodge-podge of cognitive scales and tests 
with many lacking widespread use and validation in PD 
(Defer et al 1999; Saint-Cyr et al 2000; Pillon et al 2002; 
Burn et al 2006; Voon et al 2006). Emre et al (2004), Giladi 
et al (2003), Fogelson et al (2003), and Reading et al (2002) 
used cognitive scales that were assessed and validated in 
AD (ADCS-GCIS, ADCS-ADL, NPI) without signiﬁ  cant 
validation in PDD. Miyasaki et al (2006) identiﬁ  ed the most 
accurate screening tools for PDD as the MMSE and the 
Cambridge Cognitive Examination (CAMcog). Both tools 
had similar sensitivities for the diagnosis of PDD; however, 
the CAMcog (94%) was more speciﬁ  c than the MMSE (77%) 
(Miyasaki et al 2006).
A more precise definition and characterization of 
mild cognitive impairment (MCI) in PD is also warranted 
(Fernandez et al 2005). We know that PD is a progressive 
illness and patients with MCI and without PD typically go 
on to develop AD over time. In patients with PD, how many 
patients have MCI and how many of these go on to develop 
PDD over time? There is much additional work that needs 
to be done in these areas to characterize and understand the 
course our patients will take as they progress.
The Montreal Cognitive Assessment (MoCA) has 
recently entered into the literature as an assessment tool 
for MCI. Unlike the MMSE, the MoCA incorporates 8 
additional cognitive domains including more complex 
visuospatial evaluation, naming, attention, memory, lan-
guage and abstraction tasks. It appears sensitive to the kind 
of deﬁ  cits that are evident in PDD (executive and visuo-
spatial dysfunction, etc.). In a validation study performed 
by Nasreddine et al (2005), the MoCA was found to have 
high sensitivity and speciﬁ  city for detecting MCI in patients Neuropsychiatric Disease and Treatment 2007:3(6) 782
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who performed in normal ranges on the MMSE. Using a 
normal cut-off score of 26/30, the MMSE had a sensitivity 
of 18% to detect MCI whereas an abnormal MoCA score 
detected 90%. While the MoCA seems to have much 
promise in detection of MCI, further validation in PD and 
PDD is necessary.
The publication of the ﬁ  rst large-scale, randomized, 
double-blind controlled trial of rivastigmine in PDD has 
generated much interest in the deﬁ  nition, recognition, and 
treatment of PDD. While the clinical beneﬁ  ts of rivastigmine 
for PDD patients and their families appear moderate, and 
drop-out rates due to adverse events is a concern, this drug 
shows promise in an under recognized and under treated 
condition. Rivastigmine provides clinically meaningful 
beneﬁ  ts in cognition and activities of daily living for some 
PDD patients in the short-term (Emre et al 2004; Poewe et al 
2006); however, future studies are necessary to validate its 
use in the long-term treatment of PDD.
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